183 related articles for article (PubMed ID: 33672947)
1. HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases.
Fiori S; Todisco E; Ramadan S; Gigli F; Falco P; Iurlo A; Rampinelli C; Croci G; Pileri SA; Tarella C
Biology (Basel); 2021 Feb; 10(2):. PubMed ID: 33672947
[TBL] [Abstract][Full Text] [Related]
2. HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.
Christe L; Veloza L; Gros L; Bisig B; Blum S; Hewer E; de Leval L
Diagn Cytopathol; 2022 Dec; 50(12):E351-E356. PubMed ID: 35916333
[TBL] [Abstract][Full Text] [Related]
3. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
4. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
SahBandar IN; Sy CB; van den Akker T; Kim D; Geyer JT; Chadburn A; Cesarman E; Inghirami G; Allan JN; Siddiqui MT; Ouseph MM
Pathobiology; 2023; 90(5):356-364. PubMed ID: 36996787
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
6. [A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].
Zhang ZC; Qaio JH; Ai HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):401-6. PubMed ID: 25948193
[TBL] [Abstract][Full Text] [Related]
7. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.
Kaji D; Ota Y; Sato Y; Nagafuji K; Ueda Y; Okamoto M; Terasaki Y; Tsuyama N; Matsue K; Kinoshita T; Yamamoto G; Taniguchi S; Chiba S; Ohshima K; Izutsu K
Blood Adv; 2020 Sep; 4(18):4442-4450. PubMed ID: 32936906
[TBL] [Abstract][Full Text] [Related]
8. [Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Yang L; Lu N; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1348-1353. PubMed ID: 27784355
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib.
Nasir SA; Calavia Liano H; Manfredi C
Cureus; 2022 Aug; 14(8):e27778. PubMed ID: 36106302
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.
Paul T; Ellahie AY; Almohtasib YS; Sinha U; El Omri H
EJHaem; 2021 Aug; 2(3):545-550. PubMed ID: 35844702
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib-Induced Pleural and Pericardial Effusions.
Hailan YM; Elyas A; Abdulla MA; Yassin MA
Cureus; 2021 Oct; 13(10):e19024. PubMed ID: 34824936
[TBL] [Abstract][Full Text] [Related]
12. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.
Küçükyurt S; Eşkazan T; Ayer M; Kılıçkıran Avcı B; Hatemi İ; Eşkazan AE
Pleura Peritoneum; 2024 Mar; 9(1):39-43. PubMed ID: 38558869
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
16. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
17. HHV8-negative effusion based lymphoma: a series of 17 cases at a single institution.
Usmani A; Walts AE; Patel S; Alkan S; Kitahara S
J Am Soc Cytopathol; 2015; 4(1):37-43. PubMed ID: 31051672
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Kaiafa G; Kakaletsis N; Savopoulos C; Perifanis V; Giannouli A; Papadopoulos N; Zisekas S; Hatzitolios AI
J Clin Pharm Ther; 2014 Feb; 39(1):102-5. PubMed ID: 24188312
[TBL] [Abstract][Full Text] [Related]
19. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
20. [Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].
Yang S; Qin YZ; Lai YY; Shi HX; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1013-1019. PubMed ID: 33445849
[No Abstract] [Full Text] [Related]
[Next] [New Search]
